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ABSTRACT
Hypoxia is frequent in solid tumors and linked to aggressive phenotypes and 
therapy resistance. We explored expression patterns of the proposed hypoxia marker 
HIF-1α in endometrial cancer (EC) and investigate whether preoperative functional 
imaging parameters are associated with tumor hypoxia. Expression of HIF-1α was 
explored both in the epithelial and the stromal tumor component. We found that low 
epithelial HIF-1α and high stromal HIF-1α expression were significantly associated 
with reduced disease specific survival in EC. Only stromal HIF-1α had independent 
prognostic value in Cox regression analysis. High stromal HIF-1α protein expression 
was rare in the premalignant lesions of complex atypical hyperplasia but increased 
significantly to invasive cancer. High stromal HIF-1α expression was correlated 
with overexpression of important genes downstream from HIF-1α, i.e. VEGFA and 
SLC2A1 (GLUT1). Detecting hypoxic tumors with preoperative functional imaging 
might have therapeutic benefits. We found that high stromal HIF-1α expression 
associated with high total lesion glycolysis (TLG) at PET/CT. High expression of a 
gene signature linked to hypoxia also correlated with low tumor blood flow at DCE-
MRI and increased metabolism measured by FDG-PET. PI3K pathway inhibitors were 
identified as potential therapeutic compounds in patients with lesions overexpressing 
this gene signature. In conclusion, we show that high stromal HIF-1α expression 
predicts reduced survival in EC and is associated with increased tumor metabolism at 
FDG-PET/CT. Importantly; we demonstrate a correlation between tissue and imaging 
biomarkers reflecting hypoxia, and also possible treatment targets for selected 
patients.
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INTRODUCTION
Endometrial cancer (EC) is the most common 
gynecologic carcinoma in western countries, and the 
incidence is increasing [1]. Similar to other solid tumors, 
hypoxia is an aggressive feature in EC, and may also 
be used for selecting patients for treatments targeting 
biological changes related to hypoxia [2–4]. Hypoxia-
inducible factor (HIF) proteins orchestrate the expression 
of numerous genes important for cell adaption to hypoxia. 
Both in cell line and clinical studies HIF-target genes 
have been demonstrated to encode proteins necessary for 
angiogenesis, metabolism, epithelial-to-mesenchymal 
transition (EMT), invasion, metastasis, stem cell 
maintenance, immune evasion and response to therapy 
[5]. HIF-1α is primarily regulated post-transcriptionally 
through proteasome degradation when oxygen is 
available, and is recognized as a marker of hypoxia [6]. 
When the oxygen level drops, HIF-1α is stabilized and 
translocated to the nucleus from where it, together with 
HIF-1β, serves as a transcription-promoting factor [6]. 
HIF-1α is recognized as a marker of poor survival in 
many solid tumors. In EC the prognostic importance of 
HIF-1α protein is not established, likely due to lack of 
consensus in immunohistochemical evaluation of tumor 
protein expression [7, 8]. For EC, also when considering 
different cellular localization of HIF-1α (nuclear vs 
cytoplasm) in the tumor cells, results are conflicting 
[9–12]. Recently the important function of the hypoxic 
tumor microenvironment in driving tumor progression 
and in the development of therapy resistance has been 
acknowledged, and in the tumor stroma HIF-1α has a key 
role which has led increased focus in clinical research to 
discover new therapeutics inhibiting this protein or its 
targets [8, 13–15]. Also, in EC, stromal protein expression 
signatures have been shown to be correlated to aggressive 
clinicopathological features, and also, gene expression in 
tumor cells to be correlated to expression of downstream 
proteins in the stroma, indicating an important role of the 
microenvironment in endometrial carcinogenesis [16]. 
Advanced imaging techniques using dynamic 
contrast-enhanced magnetic resonance imaging (DCE-
MRI) and positron emission tomography/computed 
tomography (PET/CT) enable visualization and 
quantification of functional tumor characteristics in vivo. 
In uterine cancers, these imaging techniques have been 
employed to depict alterations in tumor microstructure, 
microcirculation and metabolism relevant for clinical 
phenotype and prognosis, and some of these imaging 
findings have a putative link to tumor hypoxia [2, 17–19]. 
In EC, low tumor blood flow on DCE-MRI is associated 
with reduced progression free survival [18], and increased 
microvascular proliferation, a marker of activated 
angiogenesis, which may also be related to tumor hypoxia 
[2]. Similarly, in cervical cancer low values for the DCE-
MRI parameter ABrix were reported to be linked to a 
hypoxic tumor phenotype, demonstrated by upregulation 
of hypoxia response genes and increased HIF-1α protein 
expression [17]. The important roles of HIF-1α and 
hypoxia in therapy resistance have been found to be 
reversed by inhibiting or deleting HIF-1α [20–23]. Hence, 
understanding the biologic mechanisms involved in tumor 
hypoxia is therefore important to develop novel targeted 
treatment strategies and to select the patients most likely 
to respond to this treatment. Hence, if functional imaging 
methods are able to depict and quantify changes in tumor 
hypoxia during therapy, this potentially provides early 
non-invasive predictive markers of response to hypoxia 
targeting therapies.
In the present study we explore HIF-1α expression in 
EC in relation to preoperative functional imaging markers 
reflecting tumor microvasculature and metabolism, and 
find these parameters to be linked. Additionally, we 
investigate to what extent markers of hypoxia in tumor 
tissue and from preoperative imaging are reflected in a 
clinical phenotype. Finally, we discuss how this could 
assist in the optimization and individualization of EC 
treatment.
RESULTS
827 patients with comprehensive clinical data 
available were included in this population based and 
prospective patient series. Endometrial tissue from 
hysterectomy specimen were collected and routinely 
investigated by pathologist at Haukeland University 
Hospital and classified as complex atypical hyperplasia 
(CAH) (n = 80), endometrioid EC (n = 612) and non-
endometrioid EC (n = 135). A subset of 282 patients 
had fresh frozen tissue available for RNA extraction 
and gene expression analysis. Also overlapping with the 
clinical annotated patient series, 164 had been subject to 
preoperative DCE-MRI and 108 had preoperative FDG-
PET/CT.
Stromal HIF-1α expression is an independent 
prognostic marker in endometrial carcinomas
We investigated expression patterns of HIF-1α in 
both the stromal and the epithelial tumor component in EC. 
Low tumor epithelial HIF-1α protein expression was more 
often observed in patients with non-endometrioid subtype, 
high histological grade, deep myometrial invasion, 
lymph node metastasis, high International Federation of 
Gynecology and Obstetrics (FIGO) stage and in tumors 
with loss of hormone receptors (Table 1, Figure 1A). Low 
epithelial HIF-1α expression was significantly associated 
with reduced disease specific survival in EC (n = 747, 
p = 0.007) (Figure 1B). On the other hand, high HIF-
1α expression in the tumor stroma was significantly 
more frequent in patients with non-endometrioid tumor 
subtype, high grade tumors, lymph node metastasis, high 
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FIGO stage and in tumors with loss of hormone receptors 
(Table 2, Figure 1C). In addition, high expression of 
HIF-1α in the tumor stroma was significantly associated 
with reduced survival (p = 0.005) (Figure 1D) and tend 
to be more frequent in lesions with low epithelial HIF-
1α expression (p = 0.24, data not shown). Full sections 
of a small subset of patients (n = 29) were explored for 
epithelial and stromal HIF-1α expression in correlation 
to high through-put analysis of TMAs. We found protein 
expression score in full sections to correlate well with 
expression scores from TMAs for both epithelial and 
stroma HIF-1α (p = 0.04 and p = 0.003, respectively) 
(Supplementary Table 1). Importantly, high stromal HIF-
1α expression remained an independent unfavorable 
prognostic factor (hazard ratio (HR) of 1.7, p = 0.04) in 
a Cox proportional hazards model, when adjusted for 
epithelial HIF-1α expression, patient age, histological 
type and grade, myometrial invasion and lymph node 
metastasis (Table 3), epithelial HIF-1α expression failed 
to reach statistical in the same multivariate analysis 
(p = 0.97). When including hormone receptor status 
in the multivariate analysis, neither HIF-1α stromal 
protein expression nor epithelial HIF-1α expression were 
significant prognostic markers. Notably, in patients with 
hormone receptor expression loss, high stromal HIF-1α 
protein expression is associated with decreased survival 
(p = 0.01), and there was also a tendency in multivariate 
analysis (p = 0.07). Interestingly, high HIF-1α expression 
in stromal cells was almost non-existing in premalignant 
lesions, but was frequently observed in low grade 
endometrioid EC lesions (p < 0.001) (Figure 1C). 
Stromal HIF-1α expression correlates to gene 
sets representing inflammation and cell cycle 
regulation and to high metabolic tumor activity 
measured by FDG-PET/CT 
We were puzzled by the strong prognostic 
significance of stromal HIF-1α protein expression, and the 
observed absence of stromal expression in premalignant 
lesions. We therefore explored gene expression alterations 
in tumor tissue in relation to high stromal HIF-1α 
protein expression. The genes VEGFA and SLC2A1 are 
regulated by HIF-1α and strongly linked to angiogenesis 
and glycolysis, respectively. We found gene expression 
value of VEGFA and SLC2A1 in the tumor component 
to be significantly positively correlated to stromal 
HIF-1α (Supplementary Figure 1). We did not find any 
difference in expression of HIF-1α mRNA in relation to 
histological type and grade (Supplementary Figure 2A), 
while mRNA expression levels of VEGFA and SLC2A1 
were significantly higher in the more aggressive histologic 
phenotypes (Supplementary Figure 2B–2C). To further 
explore molecular alterations in premalignant and 
malignant tumors with high stromal HIF-1α, we performed 
a Gene Set Enrichment Analysis (GSEA). Using Gene 
Ontology (GO) annotated gene sets supplied by the Broad 
Institute; inflammation and cell cycle regulation were 
Table 1: Association between epithelial HIF-1α expression and clinicopathological phenotype and 
hormone receptor status in endometrial cancer patients
Variable Categories
Epithelial HIF-1α protein expression
Low % (N) High % (N) P*
Histological type & grade EEC Grade 1–2 76 (373) 24 (119) 0.03
N = 735 EEC Grade 3 82 (88) 18 (20)
NEEC 86 (116) 14 (19)
Myometrial infiltration < 50% 75 (339) 25 (114) 0.002
N =732 > 50% 85 (236) 15 (43)
Lymph node metastasis No 76 (406) 24 (126) 0.004
N=596 Yes 92 (59) 8 (5)
FIGO stage (2009) I/II 76 (473) 24 (147) 0.001
N = 735 III/IV 90 (104) 10 (11)
ERα protein expression High 76 (412) 24 (128) 0.01
N = 727 Low 85 (159) 15 (28)
PR protein expression High 76 (426) 24 (133) 0.005
N = 727 Low 86 (145) 14 (23)
Abbreviations: HIF, hypoxia-inducible factor; EEC, endometrioid endometrial cancer; NEEC, non-endometrioid endometrial 
cancer; ER, estrogen receptor; PR; progesterone receptor; N, number of patients assessed for epithelial HIF-1α protein 
expression. *Chi-square test.
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identified as activated in lesions with high stromal HIF-1α 
expression as compared to lesions with low stromal HIF-
1α expression (Supplementary Table 2).
The FDG-PET parameters total lesion glycolysis 
(TLG) was significantly higher in tumors with high 
stromal HIF-1α expression (n = 99, p = 0.02; Table 4 and 
Figure 2). Furthermore, high stromal HIF-1α expression 
tended to be associated with higher tumor maximum and 
mean standardized uptake value (SUVmax, SUVmean) and 
metabolic tumor volume (MTV) (p ≤ 0.17 for all; Table 4). 
No significant associations were observed between 
the metabolic PET parameters and epithelial HIF-1α 
expression or between the functional MRI parameters and 
both expression categories of HIF-1α expression (Table 4). 
However, high tumor volume estimated by MRI tended 
to be associated with high stromal HIF-1α expression 
(p = 0.21) (Table 4).
Hypoxia gene signature score is associated with 
tumor mRNA expression of related genes and 
functional imaging parameters and suggests 
treatment targets 
When applying a published hypoxia gene signature 
based on DCE-MRI in cervical cancer [17] to our EC 
dataset, the hypoxia gene signature score was significantly 
anti-correlated to tumor blood flow (p = 0.01) (Figure 3A). 
Also, hypoxia signature score was correlated to tumor 
volume (p = 0.05) and tended to be correlated to mean 
apparent diffusion coefficient (ADC), representing 
cellular density (p = 0.07) (data not shown). Furthermore, 
SUVmean, SUVmax and TLG were positively correlated 
with expression of the same hypoxia gene signature score 
(p ≤ 0.03 for all) (Figure 3B–3D), and so were HIF-1α, 
VEGFA and SLC2A1 mRNA expression (p <  0.001 for all) 
(Figure 3E–3G). High stromal HIF-1α protein expression 
also tended to be correlated to this hypoxia gene signature 
(p = 0.06, data not shown).
We queried connectivity map (CMap) (version 2) 
[24] for compounds anti-correlated to gene expression in 
lesions expressing high hypoxia signature score versus 
low hypoxia signature score, to identify drugs with 
potential to treat patients with hypoxic tumors. The PI3K 
inhibitor LY294002 emerged as top-ranked along with the 
HDAC inhibitor Trichostatin A and the HSP90 inhibitor 
Tanespimycin (p < 0.001 for all) (Supplementary Table 3).
In our patient cohort with available gene expression 
data, 83 of 282 patients had received adjuvant chemo- 
or radiotherapy. Consistent with previous findings [22], 
radiotherapy treated patients (n = 25) with high hypoxia 
signature score (n = 20) tended to have decreased overall 
survival (p = 0.16) (data not shown). 
Cancer associated fibroblasts express HIF-1α in 
endometrial cancer lesions
The histological appearance of the stromal cells 
with high HIF-1α protein expression, including irregular 
branched cytoplasm, suggested these to be cancer 
associated fibroblasts (CAFs). There are numerous 
Table 2: Association between stromal HIF-1α expression and clinicopathological phenotype and 
hormone receptor status in endometrial cancer patients
Variable Categories
Stromal HIF-1α protein expression
High % (N) Low % (N) P*
Histological type & grade EEC Grade 1–2 24 (113) 76 (365) 0.001
N = 691 EEC Grade 3 37 (37) 63 (63)
NEEC 37 (42) 63 (71)
Myometrial infiltration < 50% 27 (116) 73 (317) 0.5
N = 688 > 50% 29 (75) 71 (180)
Lymph node metastasis No 29 (144) 71 (360) 0.03
N = 558 Yes 43 (23) 57 (31)
FIGO stage (2009) I/II 26 (153) 74 (438) 0.007
N =  691 III/IV 39 (39) 61 (61)
ERα protein expression High 23 (121) 77 (405) < 0.001
N =  684 Low 43 (68) 57 (90)
PR protein expression High 23 (128) 77 (417) < 0.001
N = 683 Low 44 (61) 56 (77)
Abbreviations: HIF, hypoxia-inducible factor; EEC, endometrioid endometrial cancer; NEEC, non-endometrioid endometrial 
cancer; ER, estrogen receptor; PR; progesterone receptor; N, number of patients assessed for stromal HIF-1α protein 
expression. *Chi-square test.
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Figure 2: Stromal HIF-1α protein expression correlated to 18FDG PET/CT markers. Total lesion glycolysis (TLG) assessed 
by FDG-PET/CT in primary endometrial carcinoma lesions compared to stromal HIF-1α protein expression (A). FDG-PET/CT and HIF-1α 
expression in a 77-year-old patient with a non-endometrioid endometrial cancer (NEEC), FIGO stage 1B: PET/CT exhibits a large FDG-
avid uterine tumor (white arrows) with high TLG and the tumor had high stromal HIF-1α expression (black arrows) (B) FDG-PET/CT and 
HIF-1α expression in a 58-year-old patient with endometrioid endometrial cancer (EEC), grade 2, FIGO stage 1A:  PET/CT exhibits a small 
uterine lesion (white arrows) with low TLG and the tumor had low stromal HIF-1α expression (black arrows) (C). Ep: epithelial tumor 
compartment. St: stromal tumor compartment.
Figure 1: HIF-1α protein expression is a prognostic marker. (A and C) Percentage of patients with low epithelial and high 
stromal HIF-1α expression in complex atypical hyperplasia (CAH), endometrioid endometrial carcinoma (EEC) grade 1, 2 and 3 and non-
endometrioid subtype (NEEC). Number of patients indicated above the bars. Total number of patients indicated under the graph. Given 
p-values are calculated between the indicated groups using Chi-squared test. (B and D) Kaplan-Meier curves depicting disease specific 
survival in endometrial cancer (EC) patients according to high or low HIF-1α epithelial (B) and stromal (D) protein expression. For each 
category: number of cases (number of disease specific deaths).
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Table 3: Prognostic value of epithelial and stromal protein expression of HIF-1α in relation to 
established prognostic factors in endometrial cancer
Variable N (%)
Unadjusteda Adjusted
HR 95% CI P* HR 95% CI P*
Age at treatment (mean=64.1) 557 1.1 1.0–1.1 < 0.001 1.0 1.0–1.1 0.009
Histological type & grade
 Endometrioid Grade 1–2 383 (68.8) 1 1
 Endometrioid Grade 3 79 (14.2) 6.6 3.1–13.6 < 0.001 4.8 2.2–10.0 < 0.001





351 (63.0) 1 1
206 (37.0) 3.8 2.3–6.4 2.3 1.3–4.1
Lymph node metastasis < 0.001 < 0.001
 No 503 (90.3) 1 1
 Yes 54 (9.7) 8.0 4.8–13.3 3.0 1.7–5.4
Epithelial HIF-1α 0.03 0.970
 Low 434 (77.9) 2.5 1.1–5.6 1 0.4–2.5
 High 123 (22.1) 1 1.0
Stromal HIF-1α 0.004 0.04
 Low 391 (70.2) 1 1
 High 166 (29.8) 2.1 1.3–3.4 1.7 1.0–2.9
HIF, hypoxia-inducible factor; CI, confidence interval; HR, hazard ratio; N, number of cases. aUnadjusted (univariate) 
analysis conducted in 557 patients with data available for all variables in the adjusted (multivariate; including all listed 
variables) analysis. *Cox proportional hazard model.
Figure 3: Hypoxia gene signature correlates to imaging and tissue biomarkers. A pre-defined hypoxia gene signature [17] 
correlates to DCE-MRI parameter in 91 primary endometrial cancer (EC) lesions (A), FDG-PET/CT in 48 primary EC lesions (B–D) and 
expression of relevant genes (E–G) in 282 patients with complex atypical hyperplasia (CAH, n = 22) and primary endometrial cancer (EC, 
n = 260). rs = correlation coefficient.
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protein markers expressed by CAFs, however none are 
uniquely expressed in these cells [25]. We therefore 
performed simultaneously IHC staining for HIF-1α and 
common leukocyte antibody (CD45) in a subset of tumor 
samples (n = 95), to exclude that the HIF-1α expressing 
cells in the stroma are tumor associated macrophages 
(TAMs) or tumor infiltrating lymphocytes (TILs). Despite 
some leucocytes and occasional granulocytes staining 
positive for CD45, most of the HIF-1α positive cells 
did not express CD45 (Figure 4A). Furthermore, a gene 
signature derived from breast cancer exhibiting different 
gene expression patterns in CAFs and fibroblasts from 
non-cancerous tissue [26], demonstrated a significantly 
increased signature score in endometrial lesions with 
high stromal HIF-1α expression (p = 0.001) (Figure 4B). 
This CAF signature was significantly higher in low grade 
endometrioid cancer than in CAH (p = 0.001) and was 
also positively correlated to HIF-1α and SLC2A1 mRNA 
expression (p < 0.001) (Figure 4C–4E).
DISCUSSION
In this large population based study of EC patients, 
we demonstrate the negative prognostic impact of 
high stromal and low epithelial HIF-1α expression. 
Furthermore, imaging markers of increased tumor 
metabolism and low tumor blood flow are associated with 
overexpression of stromal HIF-1α and a hypoxia gene 
signature. Our findings support that tumor hypoxia may 
be important in EC progression, and reveal that functional 
preoperative imaging by DCE-MRI and FDG-PET/CT 
could depict and quantify functional alterations relevant 
for tumor hypoxia in EC. 
We show that stromal and epithelial HIF-1α 
expression tend to be inversely correlated, and that high 
stromal HIF-1α expression and low epithelial HIF-1α 
expression is associated with reduced survival. Similar to 
our findings, stromal hypoxia (represented by increased 
HIF-2α and downstream proteins) has been shown to be 
a negative prognostic factor in colorectal cancer, whereas 
epithelial tumor protein expression had no prognostic 
significance [27]. Hypoxia is frequently observed in solid 
tumors [15] and is believed to promote tumor cells to 
become more invasive and aggressive [28]. Even though 
hypoxia is a dynamic process in tumor tissue, multiple 
protein markers have been demonstrated to represent this 
biological state. HIF-1α is one of the most important, in 
addition to HIF-2α, carbonic anhydrase (CA) IX, glucose 
transporter (GLUT) 1 and osteopontin (OPN) [29]. HIF-2α 
and HIF-1α are structurally similar; however, HIF-2α is 
Table 4: Tumor HIF-1α protein expression pattern in relation to preoperative functional MRI 
and metabolic FDG-PET/CT parameters of endometrial cancer lesions
Imaging parameter 
Epithelial HIF-1α Stromal HIF-1α
Low High High Low
Mean (N) Mean (N) P* Mean (N) Mean (N) P*
MRI
Fb (ml/100 ml/min) 49.7 (124) 48.0 (37) 0.99 47.5 (48) 50.6 (109) 0.67
Ktrans (/min) 0.037 (122) 0.034 (37) 0.64 0.038 (48) 0.035 (107) 0.27
kep (/min) 0.42 (122) 0.44 (36) 0.29 0.44 (48) 0.42 (106) 0.22
Ve (ml/100 ml) 11.4 (122) 9.1 (36) 0.23 11.7 (48) 10.4 (106) 0.59
IAUGC (mMs) 69 (124) 68 (37) 0.81 69 (48) 69 (109) 0.80
ADC (× 10-6 m2/s) 800 (123) 789 (36) 0.50 787 (48) 802 (107) 0.64
Volume (ml) 22 (124) 15 (37) 0.48 30 (48) 16 (109) 0.21
FDG PET-CT
SUVmax (g/ml) 14.8 (75) 14.1 (27) 0.79 16.0 (29) 14.0 (71) 0.17
SUVmean (g/ml) 5.9 (75) 5.8 (26) 0.76 6.5 (28) 5.6 (71) 0.06
MTV (ml) 33 (77) 24 (29) 0.13 45 (30) 25 (74) 0.09
TLG (g) 235 (75) 169 (26) 0.43 336 (28) 173 (71) 0.02
Abbreviations: HIF, hypoxia-inducible factor; MRI, magnetic resonance imaging; FDG-PET/CT, fluorodeoxyglucose 
positron emission tomography/computed tomography; N, number of cases; Fb, blood flow; Ktrans, transfer from blood to EES; 
kep, transfer constant from blood extravascular extracellular space (EES) to blood; Ve, fractional volume of EES; IAUGC, 
integrated area under the concentration time curve; ADC, apparent diffusion coefficient; SUVmax, maximum standard uptake 
value; SUVmean, mean standard uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis.*Mann-Whitney 
U-test.
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thought to be less important in EC, with detected HIF-2α 
expression in less than 20% of tumor cells [30]. Literature 
evaluating the prognostic relevance of HIF-1α protein 
expression patterns in EC is conflicting. Studies exploring 
protein expression in both nucleus and cytoplasm of the 
tumor cells have demonstrated HIF-1α to be a negative 
prognostic factor both in uni- and multivariate survival 
analysis [9]; while others have failed to find a correlation 
with survival [10]. Also in studies exploring only the 
nuclear expression, the prognostic value of HIF-1α is 
not established [11, 12]. The inverse prognostic impact 
of stromal and epithelial HIF-1α protein expression 
we observe, may explain some of the discrepancies in 
reported prognostic impact of HIF-1α in the literature. Our 
approach, assessing HIF-1α protein expression patterns 
separately in the epithelial cells and the stromal cells has, 
to our knowledge, not previously been described in EC. 
Our finding of high stromal HIF-1α expression in 
primary cancers and very low expression in premalignant 
lesions suggests that HIF-1α positive cells in the tumor 
stroma are important in early steps of endometrial 
carcinogenesis. Histological characteristic of these cells 
points towards fibroblasts; this is also the most abundant 
stroma cell type [31]. In our patient cohort HIF-1α 
expressing cells in the stroma do generally not co-express 
CD45; indicating that stromal HIF-1α positive cells are not 
immune derived (TILs and TAMs). The CAF gene signature 
identified to be overexpressed in lesions overexpressing 
stromal HIF-1α supports this. The important role of tumor 
fibroblasts in tumor initiation and progression is well-
established [32, 33]. CAFs have recently been recognized 
as important drivers of tumor growth and angiogenesis, and 
also crucial for the metabolic shift to glycolysis [25, 34, 35]. 
In line with this, the CAF gene signature is strongly linked 
to HIF-1α and SLC2A1 mRNA level, and correlates to 
early invasive phenotype (endometrioid EC grade 1 and 2). 
The tumor microenvironment is increasingly recognized as an 
important contributor to cancer development and progression 
[36], and the genetic stability of the cells comprising the 
stroma makes it an attractive target for therapy [31]. The cells 
in the tumor stroma, including tumor infiltrating lymphocytes 
(TILs), tumor associated macrophages (TAMs) and cancer 
associated fibroblasts (CAFs) have been demonstrated to play 
different roles in tumor development and progression under 
the influence of hypoxia and HIF-1α [3, 6, 25, 37]. CAFs, 
the most abundant cell type in the tumor stroma, have been 
demonstrated to have an important role in cancer initiation 
and the metastatic step, and also CAFs are induced by 
HIF-1α and a key source of VEGF, which is essential in 
tumor angiogenesis [25, 31]. 
Figure 4: Carcinoma associated fibroblasts (CAFs) gene signature overexpressed in lesions of high stromal HIF-1α 
expression. (A) Immunohistochemical double staining of CD45 (brown) and HIF-1α (red) simultaneously, picture demonstrating few 
double stained cells (40× magnification). (B) CAF gene signature according to high or low stromal HIF-1α protein expression. (C) CAF 
signature score in patients with complex atypical hyperplasia (CAH), endometrioid endometrial cancer (EEC) grade 1, 2 and 3, and non-
endometrioid endometrial cancer (NEEC). (D) CAF signature score correlated to HIF-1α mRNA level. (E) CAF signature score correlated 
to SLC2A1 (GLUT1) mRNA level. rs = correlation coefficient.
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We show that the metabolic tumor marker TLG 
is significantly positively correlated to stromal HIF-1α 
protein expression. This is also true for gene expression of 
SLC2A1, indicating that energy production by glycolysis 
(aerobic or anaerobic) is the preferred pathway in these 
tumors [35]. Concurrently, SUVmax, SUVmean and MTV, by 
FDG-PET/CT tend to be higher in lesions overexpressing 
stromal HIF-1α. A positive correlation between tumor 
HIF-1α protein expression and tumor FDG uptake has 
also been shown in squamous cell carcinoma of the 
head and neck [38, 39] and in breast cancer [40], but to 
our knowledge not previously in EC. In line with the 
metabolic shift we observe in tumors overexpressing 
stromal HIF-1α, we find that a hypoxia gene signature 
(based on DCE-MRI derived parameters in cervical 
cancer) [17] is associated with low tumor blood flow (Fb) 
and high tumor metabolism (SUVmax, SUVmean and TLG), 
further suggesting a link between these imaging markers 
and tumor hypoxia. The positive correlation between the 
same hypoxia gene signature and HIF-1α, VEGFA and 
SLC2A1 suggests that the imaging parameters reveal 
real functional aspects reflecting the oxygen status in 
the tumor. Importantly, our CMap query indicates well-
known anti-neoplastic substances like LY294002 (a 
PI3K inhibitor), Trichostatin A (a HDAC inhibitor) and 
Tanespimycin (a HSP90 inhibitor) as promising potential 
treatment options for patients with increased expression of 
the hypoxia gene signature. Also, these drugs reportedly 
down-regulate HIF-1α and sensitize tumors for radiation 
therapy [41, 42]. In endometrial cancer cell lines inhibition 
of the PI3K pathway is demonstrated to sensitize cancer 
cells to radiotherapy through down regulation of HIF-1α 
[13]. Additionally, direct suppression of HIF-1α increased 
cell death after radiation, indicating that combined PI3K- 
and HIF-1α inhibition might potentiate the treatment 
effect [13]. Furthermore, blood flow, assessed by MRI is 
anti-correlated to this hypoxia gene signature, and could 
represent a non-invasive method of selecting patients for 
these treatment options, however in our cohort with gene 
expression data; too few patients have received adjuvant 
therapy to address this question.
For the subset of patients with preoperative DCE-
MRI we did not find any significant correlations between 
MRI derived structural (ADC, volume) or functional (Fb, 
Ktrans, kep, Ve and IAUGC) tumor parameters and the 
expression of stromal or epithelial HIF-1α. This contrasts 
a previous study in EC, reporting an association between 
low blood flow (Fb) at preoperative DCE-MRI and 
increased tumor microvascular proliferation, putatively 
linked to tumor hypoxia. Thus, although Fb has been 
linked to increased microvascular proliferation in EC, it is 
not proven to be the best marker of hypoxia [2].
We find stromal HIF-1α expression to be highly 
significantly associate with SLC2A1 mRNA expression 
where the corresponding protein, GLUT1, is known as 
an important protein facilitating increased glycolysis on 
which the cancer cells and hypoxic cells are dependent 
[36]. Additionally, stromal HIF-1α expression is highly 
significantly correlated to VEGFA mRNA expression. 
HIF-1α orchestrates downstream genes essential to the 
cells’ adaption to hypoxia [37], and HIF-1α is an important 
transcription inducer for numerous growth factors and 
cytokines in tumor angiogenesis, most importantly VEGFA 
[43]. In this respect, the hypoxic influence of the stroma 
has been suggested to be more important than the effect on 
the tumor cells [37]. Inhibition of HIF-1α has been shown 
to increase the effect of radiotherapy, proposed to be due 
to the selective killing of hypoxic cells, which are not 
sensitive to the DNA damaging effect of radiotherapy [22]. 
Other mechanisms that might be involved are reduced 
mitochondrial oxygen consumption, normalization of 
microvasculature, as well as loss of stromal ability to adapt 
to post-radiation tumor ischemia [21, 22]. Also, hypoxia 
and HIF-1α have been shown to induce epithelial-to-
mesenchymal-transition (EMT), increasing the metastatic 
potential of carcinomas [28]. 
In conclusion, high stromal HIF-1α is associated 
with an aggressive histological subtype and with reduced 
disease specific survival in EC. Lesions with high 
stromal HIF-1α expression exhibited increased tumor 
metabolism at FDG-PET/CT, and functional PET/CT 
and DCE-MRI parameters were correlated to previously 
published hypoxia gene signature scores. Our findings 
support that tissue markers of hypoxia are reflected in 
clinical phenotype and associated with functional imaging 
markers in EC. These preoperative imaging markers, 
in combination with molecular tissue markers, seem 
promising and should be further studied to guide selection 
of patients for novel treatment algorithms targeting 
hypoxia in EC.
MATERIALS AND METHODS
Patient and tissue samples
Patients surgically treated for EC or CAH at 
Haukeland University Hospital between May 2001 
and January 2015 were included in the study. Written 
informed consent was obtained from all patients for the 
collection of imaging data and specimens for biomarker 
studies included in an institutional review board-approved 
protocol (Rek Vest 2009/2315).
Tumor samples were obtained from hysterectomy 
specimens and collected in the Bergen Gynecologic 
Cancer Biobank, and linked to clinical and 
histopathological data. In total, 827 patients with primary 
EC (n = 747) and CAH (n = 80) with available IHC 
staining for HIF-1α were included. Imaging of patients 
with primary EC was implemented in the preoperative 
protocol for patients with primary EC from June 2009 for 
DCE-MRI and from June 2011 for FDG-PET/CT. 164 and 
108 patients with available tissue for protein expression 
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had undergone preoperative DCE-MRI and FDG-PET/CT, 
respectively. A subset of 22 CAH and 260 EC patients had 
fresh frozen tissue used for RNA extraction and mRNA 
analysis. Clinical information included age at primary 
treatment (in primary EC) or diagnosis (in CAH), body 
mass index (BMI), menopausal status, parity, primary 
surgical treatment and additional therapy received. For 
patients with EC, FIGO stage, histologic subtype, grade 
and follow-up data were recorded.
Written informed consent was obtained from all 
patients for the collection of imaging data and specimens 
for biomarker studies included in an institutional review 
board-approved protocol (Rek Vest 2009/2315).
Magnetic resonance imaging protocol and 
derived imaging parameters
Preoperative magnetic resonance imaging (MRI) 
was conducted on a whole-body 1.5-T MRI system 
(Siemens Avanto running Syngo v. B17, Erlangen, 
Germany) using a six-channel body coil applying a 
standardized imaging protocol [18]. To reduce motion 
artefacts 20 mg butylscopolamine bromide (Buscopan; 
Boehringer, Ingelheim, Germany) was administered 
intravenously just prior to scanning. Mean/median (range) 
interval between MRI examination and surgery was 12/9 
(1–98) days. Structural MRI included pelvic sagittal and 
axial oblique (perpendicular to the long axis of the uterus) 
T2-weighted images and axial oblique T1-weighted 
gradient-echo images. T1-weighted series were acquired 
before and after intravenous administration of gadoterate 
meglumine (Dotarem, Guerbet: 0.1 mmol gadolinium per 
kilogram of body weight, 3 ml/s injection speed) using a 
2- min delay. Pelvic diffusion weighted imaging (DWI) 
was acquired using an axial two-dimensional echo planar 
imaging (EPI) sequence with b-values of 0 and 1000 s/mm2 
with calculation of ADC maps. Pelvic DCE-MRI was 
acquired with 12 axial slices using a three-dimensional 
(3D) spoiled gradient echo (FLASH) sequence with 
a temporal resolution of 2.49 s [18] and a total of 160 
dynamic scans.
Tumor ADC values were extracted in regions of 
interest (ROIs) which were manually drawn on the ADC 
maps in a representative part of the tumor, using the slice 
depicting the largest cross-sectional tumor area. Tumor 
ROI was also drawn on the DCE images at 2 min post-
contrast on the slice with the largest cross-sectional 
tumor area. Parametric maps were generated from the 
DCE series based on the extended Tofts kinetic model, 
as well as model free deconvolution using singular value 
decomposition for blood flow estimates [44], using 
a standardized arterial input function reported in the 
literature [45]. The following DCE-MRI tumor parameters 
were calculated: blood flow (Fb), transfer constant from 
extravascular extracellular space (EES) to blood (kep), 
transfer from blood to EES (Ktrans), volume of EES (Ve) 
and integrated area under the concentration time curve 
(IAUGC). Tumor volume was estimated by measuring the 
largest tumor diameter in three orthogonal planes (a, b, c) 
using the following equation: Tumor volume = a × b × 
c/2 [46].
FDG-PET/CT and derived imaging parameters
PET/CT was performed on a Biograph 40 True Point 
scanner (Siemens). The scanning covered from the caput 
to the proximal thigh. The protocol included 6 h of fasting 
before the imaging was conducted. 18F-FDG (322–414 
MBq) was given intravenously 60–120 min before the 
CT scan. Low-dose CT (120 kV, 50 mAs) for attenuation 
correction of the PET data was executed before the 
static emissions, which were obtained at intervals of 3 
min per bed position; subsequently, intravenous contrast 
agent (Iomerol, 350 mg iodine/mL; Bracco Imaging 
Scandinavia, AB) and negative oral contrast agent (water) 
were administered for the diagnostic CT scan (120 mV, 
240 mAs).
The PET images were fused with both the diagnostic 
and the low-dose CT images and the metabolic tumor 
measurements were performed using the low-dose fusion 
images. Mean/median (range) interval between PET-
scanning and primary treatment was 15/12 (1–102) days. 
The SUVmax was recorded, and MTV and SUVmean were 
measured in a volume of interest (VOI) including voxels 
with an SUV of more than 2.5. TLG in the tumor was also 
estimated using the following equation: TLG = SUVmean 
× MTV [19].
Oligonucleotide DNA microarray analyses
RNA was extracted from fresh frozen tumor tissue 
after selection of area of high tumor purity, according to 
the procedure as previously described [47]. The RNA was 
hybridized to Agilent Whole Human Genome Microarrays 
according to manufacturer’s instruction (www.agilent.
com). The arrays were subsequently scanned by the 
Agilent Microarray Scanner Bundle. Signal intensity was 
interpreted using the software J-Express. The majority of 
samples had tumor purity above 80% with a minimum 
threshold > 50%. The patient series with RNA microarray 
was overlapping with protein expression scores for 
epithelial HIF-1α in 250 patients (18 cases with CAH) 
and stromal HIF-1α in 238 patients (18 cases with CAH).
Transcriptional alterations were explored by GSEA 
[48]. Pre-defined gene sets supplied by the MSigDB (www.
broadinstitute.org/gsea/index.jsp) were used to compare 
gene sets with strongest differential expression between 
two groups. Hypoxia gene signature score was calculated 
in similar manner as the in the original paper, taking the 
average expression of the 31 included genes [17]. High 
hypoxia signature score was defined as the three upper 
quartiles, and low as the lowest quartiles, based on the size 
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of the groups and number of events in the quartile groups 
in a survival analysis. Significance Analysis of Microarrays 
(SAM) was used to find genes differentially expressed in 
lesions with high vs low hypoxia gene signature score. 
Genes included in further analysis had a FDR of 0 and a 
fold change above 2. 201 genes were down-regulated in 
lesions with high hypoxia signature score, and 44 genes 
were up-regulated. These gene lists were used to quire the 
publically available database Connectivity Map (CMap) 
(www.broadinstitute.org/cmap) [24] for compounds with 
the potential to reverse the hypoxic tumor state represented 
by a hypoxia gene signature. 
Immunohistochemical staining
Tissue Micro Arrays (TMAs) were prepared as 
previously described and included three 0.6 mm cylinders 
from the most representative tumor area on FFPE tissue 
blocks from all patients [49]. Immunohistochemistry (IHC) 
was performed for ERα, PR and HIF-1α in TMA slides 
as previously reported [50]. Details regarding antibodies 
and conditions are described in Supplementary Table 4. 
Hormone receptor negativity was defined as loss of protein 
expression of both ERα and PR (double negative).
The double staining procedure assessing HIF-1α 
and CD45 was conducted in a subsample of 95 patients 
in a similar manner. After microwave antigen retrieval 
was completed, Dual Endogenous Enzyme Block (Dako 
S2003) was applied (8 min), followed by Protein Block 
(Dako X0909) for 10 minutes. The two primary antibodies 
were added simultaneously and incubated for 60 minutes, 
followed by washing, and 30 min incubation with secondary 
antibodies (Goat anti-rabbit, AP (Southern Biotech 4050–
04) and EnVision+System-HRP, anti-mouse (Dako K4001). 
Alkaline Phosphatase chromogen (Liquid permanent red, 
Dako K0640) was applied, followed by HRP chromogen 
(DAB+). After counterstaining with Hematoxylin the slides 
were covered by Faramount (Dako S3025) and cover slides.
The stained slides were evaluated using the well-
established semi-quantitative staining index graded from 0–9 
as a product of staining intensity (0–3) and the area with this 
intensity (0–3) [49]. All three proteins (ERα, PR and HIF-1α) 
were assessed in the epithelial compartment of the tumor, 
and HIF-1α also in the stroma. Established cut-off values 
were applied as previously reported for ERα and PR [49, 50]. 
For epithelial and stromal HIF-1α protein expression, high 
expression was defined as upper quartile, and low expression 
as the lower three quartiles, based on the number of events in 
the quartile groups in a survival analysis.
Statistical analysis
Analyses were performed using the statistical 
software SPSS (Statistical Package of Social Science) 
version 23.0. P-values reported were two-sided, at a 
significance level of < 0.05. Differences in continuous 
data were assessed using a non-parametric Mann-
Whitney-U test. Pearson-Chi-squared test was used to 
analyze variances in categorical data. Correlation between 
epithelial and stromal HIF-1α expression in each patient 
was explored by McNemar test for paired data. Spearman 
correlation was used for assessing the association between 
continuous data. In univariate analysis of disease specific 
survival the Kaplan-Meier method (log rank test) was 
used, with date of primary surgical treatment as entry 
date and the date of death due to EC as endpoint. Cox 
proportional hazards regression analysis was used for 
multivariate analyses.
ACKNOWLEDGMENTS
We would like to thank the Department of Pathology 
at Haukeland University Hospital, and we also thank 
Ellen Valen, Reidun Kopperud, Britt Edvardsen, Kadri 
Madiisso, Hua My Hoang and Bendik Nordanger for 
outstanding technical work. 
CONFLICTS OF INTEREST
 The authors declare no conflicts of interest.
GRANT SUPPORT
HBS and ISH were supported by Helse Vest and 
the University of Bergen. HBS by the Norwegian Cancer 
Society (Harald Andersen Legat) and the Research 
Council of Norway, CK and ISH by Bergen Research 
Foundation and University of Bergen.
REFERENCES
1. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. 
Endometrial cancer. Lancet. 2015.
2. Haldorsen IS, Stefansson I, Gruner R, Husby JA, 
Magnussen IJ, Werner HM, Salvesen OO, Bjorge L, 
Trovik J, Taxt T, Akslen LA, Salvesen HB. Increased 
microvascular proliferation is negatively correlated to 
tumour blood flow and is associated with unfavourable 
outcome in endometrial carcinomas. Br J Cancer. 2014; 
110:107–114.
3. Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the 
extracellular matrix: drivers of tumour metastasis. Nat Rev 
Cancer. 2014; 14:430–439.
4. Bredholt G, Mannelqvist M, Stefansson IM, Birkeland  E, 
Bo TH, Oyan AM, Trovik J, Kalland KH, Jonassen I, 
Salvesen HB, Wik E, Akslen LA. Tumor necrosis is an 
important hallmark of aggressive endometrial cancer and 
associates with hypoxia, angiogenesis and inflammation 
responses. Oncotarget. 2015; 6:39676–39691. doi: 
10.18632/oncotarget.5344.
Oncotarget69855www.impactjournals.com/oncotarget
 5. Semenza GL. Hypoxia-inducible factors: mediators of 
cancer progression and targets for cancer therapy. Trends 
Pharmacol Sci. 2012; 33:207–214.
 6. Palazon A, Goldrath AW, Nizet V, Johnson RS. HIF 
transcription factors, inflammation, and immunity. 
Immunity. 2014; 41:518–528.
 7. Dousias V, Vrekoussis T, Navrozoglou I, Paschopoulos M, 
Stefos T, Makrigiannakis A, Jeschke U. Hypoxia-induced 
factor-1alpha in endometrial carcinoma: a mini-review of 
current evidence. Histol Histopathol. 2012; 27:1247–1253.
 8. Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, 
Mutti L, Landi S. Targeting hypoxic response for cancer 
therapy. Oncotarget. 2016; 7:13464–13478. doi: 10.18632/
oncotarget.7229.
 9. Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, 
Koukourakis MI, Tumor, Angiogenesis Research G. 
Association of hypoxia-inducible factors 1alpha and 
2alpha with activated angiogenic pathways and prognosis 
in patients with endometrial carcinoma. Cancer. 2002; 
95:1055–1063.
10. Ozbudak IH, Karaveli S, Simsek T, Erdogan G, Pestereli  E. 
Neoangiogenesis and expression of hypoxia-inducible 
factor 1alpha, vascular endothelial growth factor, and 
glucose transporter-1 in endometrioid type endometrium 
adenocarcinomas. Gynecol Oncol. 2008; 108:603–608.
11. Sadlecki P, Bodnar M, Grabiec M, Marszalek A, 
Walentowicz P, Sokup A, Zegarska J, Walentowicz-
Sadlecka M. The role of Hypoxia-inducible factor-1 alpha, 
glucose transporter-1, (GLUT-1) and carbon anhydrase 
IX in endometrial cancer patients. Biomed Res Int. 2014; 
2014:616850.
12. Seeber LM, Horree N, van der Groep P, van der Wall E, 
Verheijen RH, van Diest PJ. Necrosis related HIF-1alpha 
expression predicts prognosis in patients with endometrioid 
endometrial carcinoma. BMC Cancer. 2010; 10:307.
13. Miyasaka A, Oda K, Ikeda Y, Sone K, Fukuda T, Inaba K, 
Makii C, Enomoto A, Hosoya N, Tanikawa M, Uehara Y, 
Arimoto T, Kuramoto H, et al. PI3K/mTOR pathway 
inhibition overcomes radioresistance via suppression of the 
HIF1-alpha/VEGF pathway in endometrial cancer. Gynecol 
Oncol. 2015; 138:174–180.
14. Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku 
F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, 
Angelo LS, Vishwamitra D, Hess K, et al. Targeting hypoxia-
inducible factor-1alpha (HIF-1alpha) in combination with 
antiangiogenic therapy: a phase I trial of bortezomib plus 
bevacizumab. Oncotarget. 2014; 5:10280–10292. doi: 
10.18632/oncotarget.2163.
15. Rohwer N, Zasada C, Kempa S, Cramer T. The growing 
complexity of HIF-1alpha’s role in tumorigenesis: DNA 
repair and beyond. Oncogene. 2013; 32:3569–3576.
16. Espinosa I, Catasus L, E DA, Mozos A, Pedrola N, 
Bertolo C, Ferrer I, Zannoni GF, West RB, van de Rijn M, 
Matias-Guiu X, Prat J. Stromal signatures in endometrioid 
endometrial carcinomas. Mod Pathol. 2014; 27:631–639.
17. Halle C, Andersen E, Lando M, Aarnes EK, Hasvold G, 
Holden M, Syljuasen RG, Sundfor K, Kristensen GB, 
Holm R, Malinen E, Lyng H. Hypoxia-induced gene 
expression in chemoradioresistant cervical cancer revealed 
by dynamic contrast-enhanced MRI. Cancer Res. 2012; 
72:5285–5295.
18. Haldorsen IS, Gruner R, Husby JA, Magnussen IJ, 
Werner HM, Salvesen OO, Bjorge L, Stefansson I, 
Akslen LA, Trovik J, Taxt T, Salvesen HB. Dynamic 
contrast-enhanced MRI in endometrial carcinoma identifies 
patients at increased risk of recurrence. Eur Radiol. 2013; 
23:2916–2925.
19. Husby JA, Reitan BC, Biermann M, Trovik J, Bjorge L, 
Magnussen IJ, Salvesen OO, Salvesen HB, Haldorsen IS. 
Metabolic Tumor Volume on 18F-FDG PET/CT Improves 
Preoperative Identification of High-Risk Endometrial 
Carcinoma Patients. J Nucl Med. 2015; 56:1191–1198.
20. Zhang M, Qiu Q, Li Z, Sachdeva M, Min H, Cardona DM, 
DeLaney TF, Han T, Ma Y, Luo L, Ilkayeva OR, Lui K, 
Nichols AG, et al. HIF-1 Alpha Regulates the Response 
of Primary Sarcomas to Radiation Therapy through a Cell 
Autonomous Mechanism. Radiat Res. 2015; 183:594–609.
21. Schwartz DL, Bankson JA, Lemos R, Jr., Lai SY, 
Thittai AK, He Y, Hostetter G, Demeure MJ, Von Hoff DD, 
Powis G. Radiosensitization and stromal imaging response 
correlates for the HIF-1 inhibitor PX-478 given with or 
without chemotherapy in pancreatic cancer. Mol Cancer 
Ther. 2010; 9:2057–2067.
22. Helbig L, Koi L, Bruchner K, Gurtner K, Hess-Stumpp H, 
Unterschemmann K, Baumann M, Zips D, Yaromina A. 
BAY 87–2243, a novel inhibitor of hypoxia-induced gene 
activation, improves local tumor control after fractionated 
irradiation in a schedule-dependent manner in head and 
neck human xenografts. Radiat Oncol. 2014; 9:207.
23. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation 
activates HIF-1 to regulate vascular radiosensitivity in 
tumors: role of reoxygenation, free radicals, and stress 
granules. Cancer Cell. 2004; 5:429–441.
24. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel 
MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, 
Hieronymus H, Wei G, et al. The Connectivity Map: using 
gene-expression signatures to connect small molecules, 
genes, and disease. Science. 2006; 313:1929–1935.
25. Luo H, Tu G, Liu Z, Liu M. Cancer-associated fibroblasts: 
a multifaceted driver of breast cancer progression. Cancer 
Lett. 2015; 361:155–163.
26. Peng Q, Zhao L, Hou Y, Sun Y, Wang L, Luo H, Peng H, 
Liu M. Biological characteristics and genetic heterogeneity 
between carcinoma-associated fibroblasts and their paired 
normal fibroblasts in human breast cancer. PLoS One. 2013; 
8:e60321.
27. Cleven AH, van Engeland M, Wouters BG, de Bruine AP. 
Stromal expression of hypoxia regulated proteins is an 
adverse prognostic factor in colorectal carcinomas. Cell 
Oncol. 2007; 29:229–240.
Oncotarget69856www.impactjournals.com/oncotarget
28. Jung HY, Fattet L, Yang J. Molecular pathways: linking 
tumor microenvironment to epithelial-mesenchymal 
transition in metastasis. Clin Cancer Res. 2015; 21:962–968.
29. Swartz JE, Pothen AJ, Stegeman I, Willems SM, 
Grolman W. Clinical implications of hypoxia biomarker 
expression in head and neck squamous cell carcinoma: a 
systematic review. Cancer Med. 2015; 4:1101–1116.
30. Keith B, Johnson RS, Simon MC. HIF1alpha and 
HIF2alpha: sibling rivalry in hypoxic tumour growth and 
progression. Nat Rev Cancer. 2012; 12:9–22.
31. Quail DF, Joyce JA. Microenvironmental regulation of tumor 
progression and metastasis. Nat Med. 2013; 19:1423–1437.
32. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, 
Selig M, Nielsen G, Taksir T, Jain RK, Seed B. Tumor 
induction of VEGF promoter activity in stromal cells. Cell. 
1998; 94:715–725.
33. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev 
Cancer. 2006; 6:392–401.
34. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, 
Delaunay T, Naeem R, Carey VJ, Richardson AL, 
Weinberg RA. Stromal fibroblasts present in invasive 
human breast carcinomas promote tumor growth and 
angiogenesis through elevated SDF-1/CXCL12 secretion. 
Cell. 2005; 121:335–348.
35. Pavlides S, Vera I, Gandara R, Sneddon S, Pestell RG, 
Mercier I, Martinez-Outschoorn UE, Whitaker-Menezes D, 
Howell A, Sotgia F, Lisanti MP. Warburg meets autophagy: 
cancer-associated fibroblasts accelerate tumor growth and 
metastasis via oxidative stress, mitophagy, and aerobic 
glycolysis. Antioxid Redox Signal. 2012; 16:1264–1284.
36. Hanahan D, Weinberg RA. Hallmarks of cancer: the next 
generation. Cell. 2011; 144:646–674.
37. Palazon A, Aragones J, Morales-Kastresana A, de 
Landazuri MO, Melero I. Molecular pathways: hypoxia 
response in immune cells fighting or promoting cancer. Clin 
Cancer Res. 2012; 18:1207–1213.
38. Yamada T, Uchida M, Kwang-Lee K, Kitamura N, 
Yoshimura T, Sasabe E, Yamamoto T. Correlation of 
metabolism/hypoxia markers and fluorodeoxyglucose 
uptake in oral squamous cell carcinomas. Oral Surg Oral 
Med Oral Pathol Oral Radiol. 2012; 113:464–471.
39. Han MW, Lee HJ, Cho KJ, Kim JS, Roh JL, Choi SH, 
Nam SY, Kim SY. Role of FDG-PET as a biological marker 
for predicting the hypoxic status of tongue cancer. Head 
Neck. 2012; 34:1395–1402.
40. Alvarez JV, Belka GK, Pan TC, Chen CC, Blankemeyer E, 
Alavi A, Karp JS, Chodosh LA. Oncogene pathway 
activation in mammary tumors dictates FDG-PET uptake. 
Cancer Res. 2014; 74:7583–7598.
41. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, 
Georgescu MM, Simons JW, Semenza GL. Modulation 
of hypoxia-inducible factor 1alpha expression by the 
epidermal growth factor/phosphatidylinositol 3-kinase/
PTEN/AKT/FRAP pathway in human prostate cancer 
cells: implications for tumor angiogenesis and therapeutics. 
Cancer Res. 2000; 60:1541–1545.
42. Nakajima A, Endo H, Okuyama H, Kiyohara Y, Kimura T, 
Kamiura S, Hiraoka M, Inoue M. Radiation sensitivity 
assay with a panel of patient-derived spheroids of small cell 
carcinoma of the cervix. Int J Cancer. 2015; 136:2949–2960.
43. Semenza GL. Cancer-stromal cell interactions mediated 
by hypoxia-inducible factors promote angiogenesis, 
lymphangiogenesis, and metastasis. Oncogene. 2013; 
32:4057–4063.
44. Ostergaard L, Sorensen AG, Kwong KK, Weisskoff RM, 
Gyldensted C, Rosen BR. High resolution measurement 
of cerebral blood flow using intravascular tracer bolus 
passages. Part II: Experimental comparison and preliminary 
results. Magn Reson Med. 1996; 36:726–736.
45. Bjornerud A, Emblem KE. A fully automated method for 
quantitative cerebral hemodynamic analysis using DSC-
MRI. J Cereb Blood Flow Metab. 2010; 30:1066–1078.
46. Ytre-Hauge S, Husby JA, Magnussen IJ, Werner HM, 
Salvesen OO, Bjorge L, Trovik J, Stefansson IM, 
Salvesen HB, Haldorsen IS. Preoperative tumor size at MRI 
predicts deep myometrial invasion, lymph node metastases, 
and patient outcome in endometrial carcinomas. Int J 
Gynecol Cancer. 2015; 25:459–466.
47. Wik E, Raeder MB, Krakstad C, Trovik J, Birkeland E, 
Hoivik EA, Mjos S, Werner HM, Mannelqvist M, 
Stefansson IM, Oyan AM, Kalland KH, Akslen LA, et al. 
Lack of estrogen receptor-alpha is associated with epithelial-
mesenchymal transition and PI3K alterations in endometrial 
carcinoma. Clin Cancer Res. 2013; 19:1094–1105.
48. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, 
Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub 
TR, Lander ES, Mesirov JP. Gene set enrichment analysis: 
a knowledge-based approach for interpreting genome-
wide expression profiles. Proc Natl Acad Sci USA. 2005; 
102:15545–15550.
49. Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB. 
GATA3 expression in estrogen receptor alpha-negative 
endometrial carcinomas identifies aggressive tumors with 
high proliferation and poor patient survival. Am J Obstet 
Gynecol. 2008; 199:543 e541–547.
50. Trovik J, Wik E, Werner HM, Krakstad C, 
Helland H, Vandenput I, Njolstad TS, Stefansson IM, 
Marcickiewicz J, Tingulstad S, Staff AC, MoMa TECsg, 
Amant F, et al. Hormone receptor loss in endometrial 
carcinoma curettage predicts lymph node metastasis 
and poor outcome in prospective multicentre trial. Eur J 
Cancer. 2013; 49:3431–3441.
